 BOSTON, Oct. 05, 2022 GLOBE NEWSWIRE -- Ikena Oncology, Inc. Nasdaq: IKNA, Ikena, a targeted oncology company forging new territory in patient-directed cancer treatment, today announced that two abstracts highlighting the companys Aryl Hydrocarbon Receptor AHR antagonist program, IK-175, will be presented at the Society for Immunotherapy of Cancer SITC 37th Annual Meeting, which will be held in-person in Boston, MA and virtually on November 8-12, 2022. 